Skip header and navigation

4 records – page 1 of 1.

Imaging of ulcerative colitis

https://libcat.nshealth.ca/en/permalink/provcat33766
Massimo Tonolini, editor. --Milan: Springer , c2014.
Available Online
View e-Book
Location
Online
During the past decade, the medical and surgical treatment of ulcerative colitis has undergone dramatic advances, including the widespread use of immunomodulators, biological drugs, and restorative proctocolectomy. In order to correctly balance the risks and benefits of medical therapies and surgical procedures, there is a need for improved diagnosis of colonic disease, acute complications, extraintestinal manifestations, and early and delayed postoperative complications. Cross-sectional imagin…
Available Online
View e-Book
Other Authors
Tonolini, Massimo
Responsibility
Massimo Tonolini, editor
Place of Publication
Milan
Publisher
Springer
Date of Publication
c2014
Physical Description
1 online resource (x, 143 pages)
ISBN
9788847054097 (electronic bk.)
9788847054080
Subjects (MeSH)
Colitis, Ulcerative - diagnostic imaging
Colitis, Ulcerative - diagnosis
Radiography
Subjects (LCSH)
Ulcerative colitis - Imaging
Ulcerative colitis - Diagnosis
Colitis, Ulcerative - radiography
Colitis, Ulcerative - diagnosis
Diagnostic Imaging - methods
Diagnostic Radiology
Gastroenterology
Proctology
Abdominal surgery
Abstract
During the past decade, the medical and surgical treatment of ulcerative colitis has undergone dramatic advances, including the widespread use of immunomodulators, biological drugs, and restorative proctocolectomy. In order to correctly balance the risks and benefits of medical therapies and surgical procedures, there is a need for improved diagnosis of colonic disease, acute complications, extraintestinal manifestations, and early and delayed postoperative complications. Cross-sectional imaging techniques are therefore playing an increasing role in the assessment of ulcerative colitis and provide an essential complement to clinical data and endoscopy. This practical, illustrated volume on the role of cross-sectional imaging is aimed at radiologists, gastroenterologists, and surgeons who are engaged or interested in the diagnosis and care of patients with inflammatory bowel disease, particularly ulcerative colitis. After an overview of diagnostic imaging techniques, state-of-the-art assessment of colorectal inflammatory disease with CT colonography using water enema and bowel MRI is discussed, followed by description of the plain radiographic and CT findings in patients with acute exacerbations and surgical complications. Subsequent chapters review the diagnostic findings and role of cross-sectional imaging in the assessment of sclerosing cholangitis (with emphasis on MR cholangiopancreatography), vascular complications (particularly portal and mesenteric thrombosis), colitis-associated colorectal cancer and perianal inflammatory disease. Normal postoperative appearances and early and delayed complications in patients treated with proctocolectomy and ileal pouch-anal anastomosis are also comprehensively reviewed.
Contents
Introduction -- Medical Needs -- Intestinal Ultrasound in Ulcerative Colitis -- Water Enema Multidetector CT Colonography: Technique, Role and Imaging Findings in Ulcerative Colitis -- Magnetic Resonance Imaging of Ulcerative Colitis -- Radiographic and CT Imaging Assessment of Acute Exacerbations and Surgical Complications -- Cross-Sectional Imaging Mimics of Ulcerative Colitis -- Hepato-Bilio-Pancreatic Complications of Ulcerative Colitis -- Vascular Complications of Ulcerative Colitis -- Neoplasms in Ulcerative Colitis -- Musculoskeletal Manifestations of Ulcerative Colitis -- Surgical Perspective on Perianal Complications in Ulcerative Colitis -- Imaging of Perianal Inflammatory Disorders in Ulcerative Colitis -- Ileal Pouch-Anal Anastomosis Surgery: Surgical Techniques -- Imaging of Ileal Pouch Surgery and Related Complications.
Format
e-Book
Location
Online
Less detail

Ulcerative proctitis

https://libcat.nshealth.ca/en/permalink/chpams35311
Nova Scotia Health Authority. GI Clinic. Halifax, NS: Nova Scotia Health Authority , 2021.
Pamphlet Number
1422
Available Online
View Pamphlet
Ulcerative proctitis is a type of inflammatory bowel disease. Inflammatory bowel disease (IBD) is the general name for diseases that cause inflammation (swelling and irritation) in the intestines (“gut”). It includes ulcerative proctitis, Crohn’s disease, and ulcerative colitis. How this condition is diagnosed as well as the symptoms and treatments are reviewed.
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. GI Clinic
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2021
Format
Pamphlet
Language
English
Physical Description
1 electronic document (4 p.) : digital, PDF file
Subjects (MeSH)
Colitis, Ulcerative
Inflammatory Bowel Diseases
Subjects (LCSH)
Ulcerative colitis
Inflammatory bowel diseases
Abstract
Ulcerative proctitis is a type of inflammatory bowel disease. Inflammatory bowel disease (IBD) is the general name for diseases that cause inflammation (swelling and irritation) in the intestines (“gut”). It includes ulcerative proctitis, Crohn’s disease, and ulcerative colitis. How this condition is diagnosed as well as the symptoms and treatments are reviewed.
Responsibility
Prepared by: GI Clinic
Pamphlet Number
1422
Less detail

Ustekinumab (Stelara) therapy

https://libcat.nshealth.ca/en/permalink/chpams35722
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1695
Available Online
View Pamphlet
Your IBD health care provider believes treatment with a medication called ustekinumab may help to manage your inflammatory bowel disease (IBD). The brand name for ustekinumab is Stelara®. This pamphlet will give you basic information about ustekinumab to help you make an informed decision about whether or not to use this treatment. Topics include what ustekinumab is, how it works, how it is given, how long you will need to take it, and how much it will cost. Considerations before you start taki…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (10 p.) : digital, PDF file
Subjects (MeSH)
Ustekinumab
Inflammatory Bowel Diseases - drug therapy
Subjects (LCSH)
Inflammatory bowel diseases
Crohn's disease
Ulcerative colitis
Specialty
Medications
Abstract
Your IBD health care provider believes treatment with a medication called ustekinumab may help to manage your inflammatory bowel disease (IBD). The brand name for ustekinumab is Stelara®. This pamphlet will give you basic information about ustekinumab to help you make an informed decision about whether or not to use this treatment. Topics include what ustekinumab is, how it works, how it is given, how long you will need to take it, and how much it will cost. Considerations before you start taking ustekinumab and while you are taking it are listed. Possible side effects, information about pregnancy and breast/chest feeding, and other important things to know are included.
Notes
Previous title: Ustekinumab (Stelara) therapy for Crohn's disease
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
1695
Less detail

Vedolizumab (Entyvio) therapy

https://libcat.nshealth.ca/en/permalink/chpams35620
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program. Halifax, NS: Nova Scotia Health Authority , 2022.
Pamphlet Number
1623
Available Online
View Pamphlet
Vedolizumab (Entyvio®) is given to manage inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. This pamphlet gives you information about vedolizumab to help you make an informed decision about whether or not to use it. Topics include: a brief description of the medicine, who can take it, how it works, how it is given, how long you will need to take it, cost, precautions, and side effects. A list of symptoms to watch out for is listed. Other important things to know when und…
Available Online
View Pamphlet
Corporate Author
Nova Scotia Health Authority. Nova Scotia Collaborative IBD Program
Place of Publication
Halifax, NS
Publisher
Nova Scotia Health Authority
Date of Publication
2022
Format
Pamphlet
Language
English
Physical Description
1 electronic document (11 p.) : digital, PDF file
Subjects (MeSH)
Gastrointestinal Agents
Colitis, Ulcerative - drug therapy
Crohn Disease - drug therapy
Subjects (LCSH)
Gastrointestinal agents
Ulcerative colitis
Crohn's disease
Specialty
Medications
Abstract
Vedolizumab (Entyvio®) is given to manage inflammatory bowel disease (IBD), ulcerative colitis, or Crohn's disease. This pamphlet gives you information about vedolizumab to help you make an informed decision about whether or not to use it. Topics include: a brief description of the medicine, who can take it, how it works, how it is given, how long you will need to take it, cost, precautions, and side effects. A list of symptoms to watch out for is listed. Other important things to know when undergoing this treatment are provided.
Responsibility
Prepared by: Nova Scotia Collaborative IBD Program
Pamphlet Number
1623
Less detail